Edmundo Muniz, M.D., Ph.D.
President and Chief Executive Officer

Dr. Muniz brings over 22 years of drug development experience in oncology, Cardiovascular, and infectious disease. Prior to joining Tigris, Dr. Muniz was Vice President for Lilly Research Laboratories Global Oncology Platform at Eli Lilly and Company. At Lilly, Dr. Muniz was responsible for Phase II, III and IV clinical trials for oncology compounds worldwide and for Global Marketing Pre-launch.

Under Dr. Muniz's leadership, Lilly Oncology achieved 9 major oncology submissions worldwide, with all 9 of those already having gained approval in the US, Europe and Japan. Such projects include Dr. Muniz's extensive involvement in the development of approved oncology therapeutics Alimta® and Gemzar®. Additionally, Dr. Muniz led the launch of Lilly Oncology on Canvas: Expressions of a Woman's Cancer Journey, an international art exhibition that displays works from over 400 cancer survivors, family members, care providers and friends. Prior to joining Eli Lilly, Dr. Muniz completed a PhD in Epidemiology and International Health at the University of Michigan and later completed a residency in Preventive Medicine and a Fellowship in Epidemic Intelligence with the Centers for Disease Control and Prevention (CDC) in Atlanta.

Anne White
Chief Operating Officer, Vice President, Clinical Operations

Ms. White has 20 years of drug development experience and has held the role of COO and VP Clinical Operations at Tigris since the company’s inception in 2005. Prior to joining Tigris, Ms. White was the Chief Operating Officer for the Global Oncology Platform at Eli Lilly and Company, responsible for global clinical operations for cancer products. Ms. White's career at Eli Lilly and Company has spanned clinical development operations leadership positions in oncology, infectious diseases, and neuroscience. In her most recent position in Lilly Oncology, Ms. White was responsible for clinical operations leadership of three oncology products, both pre- and post-registration. During Ms. White's tenure, Lilly Oncology submitted 9 major applications in the US, EU and Japan and initiated over 100 clinical studies globally. She has led teams through multiple regulatory filings, including INDs, NDAs, and CTAs, and has extensive experience in partnering with Clinical Research Organizations for multi-national studies. Ms. White has also driven the in- and out-licensing of multiple products during her career. In 2005, Ms. White received the Eli Lilly's Women's Network Leadership Award in recognition for her leadership and technical skills.

Binh Nguyen, M.D., Ph.D.
Vice President of Clinical Development and Chief Medical Officer

Dr. Nguyen possesses over 15 years of experience in oncology clinical drug development and regulatory affairs. Prior to joining Tigris, Dr. Nguyen served as Executive Director of the Oncology Platform Team and of the Pharmacogenomic Program for Eli Lilly and Company. In this role, Dr. Nguyen was responsible for the overall clinical development plan with correlated translational research of numerous early- and late-stage molecules. He managed interactions with regulatory authorities in the US, Europe, and Japan, and has successfully led two defenses at the Oncologic Drug Advisory Committee (ODAC) of the US Food and Drug Administration (FDA). He has achieved successful global approvals for two drugs in six indications (mesothelioma, 1st line and 2nd line NSCLC, pancreatic, bladder, breast and ovarian cancer).

Prior to his work with Eli Lilly, Dr. Nguyen completed his medical oncology fellowship at the National Cancer Institute and was a Clinical Fellow at the Cancer Therapy Evaluation Program (CTEP), where he was responsible for the clinical development plan of investigational drugs. Dr. Nguyen was also a fellow at the Center for Drug Evaluation and Research (CDER) at the Division of Pulmonary and Oncology Drug Products of the FDA, where he was responsible for reviewing Investigational New Drug (IND) and New Drug Application (NDA) filings.